Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07025330 · ClinicalTrials.gov registry record · Phase 2
A Study of Efgartigimod in Patients With IgG4-Related Disease
A Phase 2 study of IgG4 Related Disease, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT07025330 is a Phase 2 study of IgG4 Related Disease that is actively recruiting participants, run by Stanford University. The registered enrollment target is 5 participants, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07025330, a Phase 2 study of IgG4 Related Disease, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * pancreas Participants will: * Receive efgartigimod once weekly for up to 12 weeks * Visit the clinic every one to six weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on efgartigimod
Conditions Studied
Interventions
- DRUG Efgartigimod
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07025330
The ClinicalTrials.gov registry entry for NCT07025330 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (95% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgG4 Related Disease appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod is the first listed.
NCT07025330 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07025330 about?
NCT07025330 is a clinical study titled "A Study of Efgartigimod in Patients With IgG4-Related Disease". The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * ...
What is the current status of trial NCT07025330?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-11-12. Estimated completion is 2028-06-01.
What conditions does trial NCT07025330 study?
This clinical trial studies the following conditions: IgG4 Related Disease.
What interventions are being tested in trial NCT07025330?
The interventions under investigation include: Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT07025330?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07025330 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
RECRUITING · Phase 1
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.